The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Cantor Fitzgerald analyst Kristen Kluska reiterated a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 9.81% of ...